Early detection value of miR-29a in patients with acute myocardial infarction
Frontiers in Cardiovascular Medicine · 11.05.2026 · 13
DOI: 10.3389/fcvm.2026.1744328 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 11.05.2026. Verfasst von Yanqing Wang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Hebei Medical University, Shijiazhuang, Hebei, China. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Early detection of myocardial remodeling, a critical precursor to heart failure in acute myocardial infarction (AMI), remains inadequate with current biomarkers. Preclinical studies suggest miR-29a plays a role in these processes, yet its diagnostic value in early AMI remains unclear. This study evaluates the diagnostic and prognostic potential of miR-29a as a marker for myocardial remodeling in AMI patients.
Methods
A prospective cohort study enrolled 52 patients with ST-elevation myocardial infarction (STEMI) caused by anterior descending branch occlusion, who underwent primary percutaneous coronary intervention within 12 h of symptom onset, along with 39 healthy controls.
Results
Serum miR-29a levels were significantly elevated in STEMI patients compared to controls, exhibiting a graded increase with higher SYNTAX scores. MiR-29a levels positively correlated with soluble suppression of tumorigenicity 2 (sST2), N-terminal pro-brain natriuretic peptide (NT-proBNP), and the Tei index, while showing an inverse correlation with left ventricular ejection fraction (LVEF). Receiver operating characteristic (ROC) analysis indicated that serum miR-29a holds promise as a novel biomarker for early detection of myocardial remodeling in AMI. Furthermore, the combination of miR-29a with NT-proBNP and/or sST2 significantly enhanced diagnostic accuracy compared to individual biomarkers. The triad of miR-29a, NT-proBNP, and sST2 achieved the highest area under the curve (AUC) of 0.904, with 97.4% specificity and 76.9% sensitivity.
Conclusion
Serum miR-29a shows significant potential as a biomarker for the early detection of myocardial remodeling in AMI, providing valuable diagnostic and prognostic insights.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Hebei Medical University, Shijiazhuang, Hebei, China.
- Departments of Cardiology, Hebei General Hospital, Shijiazhuang, Hebei, China.
Zitieren
APA
Wang, Y., Gao, P., Duan, Y., Su, H., Wu, H., Jia, Y., Zhang, Y., Liu, J., Li, H., Li, X., Li, W., Shi, X., Liu, T., Huang, T., & Du, R. (2026). Early detection value of miR-29a in patients with acute myocardial infarction. Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.1744328
Vancouver
Wang Y, Gao P, Duan Y, Su H, Wu H, Jia Y, et al. Early detection value of miR-29a in patients with acute myocardial infarction. Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.1744328
BibTeX
@article{Wang2026,
author = {Wang, Yanqing and Gao, Peng and Duan, Yawei and Su, Hanqi and Wu, Haibo and Jia, Yuan and Zhang, Yue and Liu, Jia and Li, Hongxiao and Li, Xiangming and Li, Wenjuan and Shi, Xiaoshuai and Liu, Tingting and Huang, Teng and Du, Rongpin},
title = {Early detection value of miR-29a in patients with acute myocardial infarction},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fcvm.2026.1744328}
}
EUVIMED